Gaining Weight on Retatrutide: Causes, Solutions, and When to Seek Help

Gaining weight on retatrutide can be alarming, especially given the drug's reputation for significant weight loss in clinical trials. Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon pathways — but individual responses vary, and short-term weight increases are not uncommon. Fluid retention, dose titration phases, metabolic adaptation, dietary habits, and underlying health conditions can all contribute to unexpected weight changes during treatment. This article explains the most likely reasons, when to seek medical advice, and how lifestyle factors can support the drug's effectiveness.

How Retatrutide Works and Its Effect on Body Weight

Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that suppresses appetite and may increase energy expenditure, but it is not yet MHRA- or EMA-licensed and individual weight loss responses vary considerably.

Retatrutide is an investigational triple receptor agonist that targets three hormonal pathways simultaneously: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple mechanism distinguishes it from existing licensed treatments such as semaglutide (GLP-1 only) or tirzepatide (GLP-1 and GIP). By activating all three receptors, retatrutide is proposed to suppress appetite, support metabolic function, and — based on preclinical and early human data — may increase energy expenditure, though this last effect requires confirmation in larger human studies.

In Phase 2 clinical trials, retatrutide has shown substantial weight loss outcomes. Data published in the New England Journal of Medicine (2023) showed average weight reductions of up to 24% over 48 weeks at the highest doses studied. These results are notable within the current pharmacological weight management landscape, though cross-trial comparisons are indirect and head-to-head data against other agents are not yet available. It is important to note that retatrutide is not yet licensed for use in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) or approved by the European Medicines Agency (EMA); it remains under clinical investigation, with Phase 3 trials ongoing.

Despite these promising findings, individual responses vary considerably. Not everyone will experience the same degree of weight loss, and some individuals may notice periods where weight does not decrease — or increases slightly. Understanding why this happens requires looking at both the proposed pharmacology of the drug and the broader context of each person's health, lifestyle, and treatment journey.

Common Reasons Weight May Increase During Treatment

Short-term weight increases during retatrutide treatment are most often caused by normal daily fluctuation, fluid retention, constipation, or inadequate appetite suppression during early dose titration rather than treatment failure.

If you are gaining weight whilst taking retatrutide, it is understandably concerning — but there are several plausible explanations that do not necessarily indicate treatment failure.

Short-term fluctuations in weight are common and can reflect changes in fluid balance, bowel habit, dietary sodium intake, or menstrual cycle phase rather than changes in fat mass. These are well-recognised causes of day-to-day scale variation and are not specific to retatrutide.

Another consideration is muscle gain, particularly if you have increased physical activity alongside treatment. Muscle tissue is denser than fat, meaning your body composition may be improving even if your overall weight appears to rise. It is worth noting, however, that GLP-1-based therapies can sometimes reduce lean muscle mass alongside fat, particularly without adequate protein intake and resistance exercise — so monitoring body composition rather than weight alone is valuable.^[8][9]

Dose titration phases may also play a role. During the early weeks of treatment, when doses are being gradually increased to minimise gastrointestinal side effects, the appetite-suppressing effects may not yet be fully established. Some individuals may inadvertently consume slightly more food during this adjustment period.

Additionally, hormonal fluctuations — including those related to thyroid function or stress-related cortisol release — can cause transient weight increases unrelated to the medication itself. Keeping a consistent record of your weight, measured at the same time of day and under the same conditions, helps identify genuine trends rather than day-to-day variation.

Factors That Can Slow or Reverse Weight Loss Progress

Metabolic adaptation, calorie-dense dietary choices, alcohol, weight-promoting medicines, and underlying conditions such as hypothyroidism or PCOS can all blunt or reverse weight loss progress during retatrutide treatment.

Several underlying factors can blunt the effectiveness of retatrutide and contribute to weight gain or a plateau during treatment.

Metabolic adaptation is one such factor — as the body loses weight, it naturally adjusts its resting metabolic rate downward in an attempt to preserve energy stores. This is a well-documented physiological response and can make continued weight loss progressively more difficult over time, even with effective pharmacotherapy.

Dietary habits remain critically important. Retatrutide reduces appetite, but it does not eliminate the impact of calorie-dense food choices. If appetite suppression leads to smaller portions of high-calorie, ultra-processed foods rather than a shift towards more nutritious options, overall caloric intake may remain higher than expected. Similarly, alcohol consumption is often overlooked — alcoholic drinks are calorie-dense and can stimulate appetite in ways that counteract the drug's effects.

Medication interactions and comorbidities should also be considered. Certain medicines — including corticosteroids, some antidepressants (such as mirtazapine), antipsychotics, and insulin — are associated with weight gain and may partially offset the benefits of retatrutide.^[10][11] If retatrutide is used alongside insulin or sulfonylureas, there is an increased risk of hypoglycaemia, which can drive compensatory eating and affect overall calorie balance; a review of diabetes medicines with your clinical team is advisable in this situation. Conditions such as hypothyroidism, polycystic ovary syndrome (PCOS), Cushing's syndrome, and conditions associated with insulin resistance (such as prediabetes or type 2 diabetes) can independently drive weight gain and should be assessed if not already managed.

Finally, psychological factors such as emotional eating, binge eating disorder, or high levels of chronic stress can undermine treatment outcomes. These are not personal failings but recognised clinical barriers to weight management that may benefit from specialist support alongside pharmacological treatment.

When to Speak to Your Doctor or Prescriber

Seek urgent medical attention for severe abdominal pain, chest pain, or significant swelling; seek prompt advice for unexplained rapid weight gain, new hormonal symptoms, or persistent gastrointestinal side effects affecting nutrition.

Because retatrutide is not yet licensed in the UK, anyone currently taking it is likely doing so within a clinical trial or specialist research programme. In either case, there should be a named clinician or research team overseeing your care, and they should be your first point of contact if you have concerns about unexpected weight gain or any other change in your health.

If you are not part of a formal trial, you should not attempt to obtain retatrutide through online or unregulated sources. Unlicensed medicines obtained outside a supervised clinical setting carry significant safety risks; speak to your GP or pharmacist if you have concerns about the legitimacy of any medicine.

You should seek prompt medical advice if you experience:

• Unexplained or rapid weight gain without an obvious dietary cause — contact your clinical team rather than waiting for your next scheduled appointment

• Severe or persistent abdominal pain, particularly pain that radiates to the back, or pain accompanied by fever or jaundice — these may be signs of pancreatitis or gallbladder disease and require urgent same-day assessment (contact NHS 111, your GP urgently, or attend A&E if symptoms are severe)

• New or worsening symptoms such as fatigue, cold intolerance, hair loss, or irregular periods, which could indicate an underlying thyroid or hormonal condition

• Persistent nausea, vomiting, or abdominal discomfort, which are known side effects of GLP-1-based therapies and may affect your ability to maintain adequate nutrition

• Mood changes or disordered eating patterns that are affecting your relationship with food

• Symptoms of low blood sugar (shakiness, sweating, confusion) if you are also taking insulin or a sulfonylurea

If you are pregnant, planning a pregnancy, or breastfeeding, inform your clinical team immediately. Based on class-level guidance for incretin-based medicines, use during pregnancy and breastfeeding is not recommended; your team can advise on appropriate contraception and alternative management.

If you experience a suspected side effect from retatrutide outside of a clinical trial, you can report it to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk. If you are enrolled in a trial, report any concerns directly to your study team or trial sponsor.

Even outside these specific triggers, if you feel that your treatment is not working as expected after several weeks at a stable dose, a review with your prescriber is entirely appropriate. NICE guidance on obesity management (NG246) emphasises the importance of regular monitoring and individualised care — principles that apply equally to emerging treatments such as retatrutide.^[15][16]

Lifestyle Factors That Support Retatrutide's Effectiveness

A diet rich in lean protein, fibre, and minimally processed foods, combined with at least 150 minutes of weekly aerobic activity and resistance training, helps maximise retatrutide's effectiveness and preserve lean muscle mass.

Pharmacological treatment for obesity works best when supported by sustainable lifestyle changes. Retatrutide is not a standalone solution, and the clinical trials that demonstrated its efficacy were conducted alongside dietary and behavioural counselling. Adopting evidence-based lifestyle strategies can help maximise your results and reduce the likelihood of weight gain during treatment.

Dietary quality is arguably the most important modifiable factor. Rather than focusing solely on calorie counting, aim for a diet rich in:

• Lean proteins (chicken, fish, legumes, eggs) — which support satiety and help preserve muscle mass

• Fibre-rich vegetables and wholegrains — which slow gastric emptying and complement the drug's appetite-suppressing effects

• Healthy fats (olive oil, avocado, nuts) — in moderate quantities to support hormonal health

• Minimally processed foods — reducing reliance on ultra-processed products that are engineered to override satiety signals

Physical activity plays a dual role: it supports energy expenditure and helps preserve lean muscle mass during weight loss, which is particularly important given that GLP-1-based therapies can sometimes reduce muscle alongside fat. Current NHS guidance recommends at least 150 minutes of moderate-intensity aerobic activity per week, combined with muscle-strengthening exercises on two or more days. If you have a long-term condition, disability, or are older, the NHS and UK Chief Medical Officers provide tailored activity guidance to help you exercise safely at a level appropriate to your circumstances.

Sleep quality and stress management are frequently underestimated. Poor sleep elevates ghrelin (the hunger hormone) and reduces leptin (the satiety hormone), directly counteracting the appetite-suppressing effects of retatrutide. Chronic stress similarly drives cortisol-mediated fat storage, particularly around the abdomen. Addressing these factors through sleep hygiene, mindfulness, or psychological support can meaningfully improve treatment outcomes.

What the Current Evidence Says About Long-Term Outcomes

Phase 2 data show substantial short-term weight loss with retatrutide, but long-term evidence beyond 48 weeks is limited; weight regain after discontinuation is anticipated based on patterns seen with other GLP-1-based agents.

Retatrutide is one of the most promising agents in the current pipeline for obesity pharmacotherapy, but it is essential to interpret the available evidence with appropriate context. The Phase 2 trial published in 2023 demonstrated substantial short-term weight loss, but long-term data — particularly beyond 48 weeks — remain limited. Phase 3 trials are ongoing (registered on ClinicalTrials.gov and the EU Clinical Trials Register), and until these are completed and reviewed by regulatory bodies such as the MHRA and EMA, the full picture of long-term efficacy and safety is not yet established.

One important consideration from existing GLP-1 receptor agonist research is the phenomenon of weight regain after discontinuation. Studies on semaglutide (STEP 1 extension trial) showed that participants regained a significant proportion of lost weight within one year of stopping treatment. It is plausible that a similar pattern may occur with retatrutide given its shared mechanisms, but this remains an extrapolation — retatrutide-specific long-term discontinuation data are not yet available, and this hypothesis awaits confirmation from Phase 3 outcomes. This underscores the importance of viewing obesity as a chronic condition requiring long-term management rather than a short-term intervention.

There is currently no established evidence that retatrutide causes sustained or unexplained weight gain in the majority of users when taken correctly. Instances of weight gain during treatment are more likely attributable to the individual factors outlined in earlier sections than to the drug itself. However, as with all emerging therapies, longer-term trial data and post-marketing surveillance will be essential to fully characterise its benefit-risk profile.

If you are participating in a trial or accessing retatrutide through a research programme, your clinical team will be monitoring outcomes closely. Engaging openly with that process — including reporting unexpected changes in weight — contributes to the broader evidence base and ensures your own care remains appropriately tailored.

Frequently Asked Questions